NCT01527110View on ClinicalTrials.gov

A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 1, 2012

Primary Completion Date

March 1, 2013

Study Completion Date

March 29, 2013

Conditions
Influenza, Human
Interventions
DRUG

Intravenous (IV) zanamivir

Zanamivir aqueous solution 10mg/mL, 600mg of IV zanamivir infusion twice daily for 5 days

Trial Locations (7)

816-0864

GSK Investigational Site, Fukuoka

247-8533

GSK Investigational Site, Kanagawa

983-0824

GSK Investigational Site, Miyagi

985-8506

GSK Investigational Site, Miyagi

700-8557

GSK Investigational Site, Okayama

581-0011

GSK Investigational Site, Osaka

432-8002

GSK Investigational Site, Shizuoka

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY